
Centogene N.V. CNTG
Annual report 2023
added 12-27-2025
Centogene N.V. Total Assets 2011-2026 | CNTG
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Centogene N.V.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 77.2 M | 92.8 M | 91.1 M | 150 M | 118 M | 76.7 M | 55.5 M | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 150 M | 55.5 M | 94.4 M |
Quarterly Total Assets Centogene N.V.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 108 M | 92 M | 96.2 M | 121 M | 145 M | 150 M | 122 M | 103 M | 113 M | 118 M | - | - | - | 76.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 150 M | 76.7 M | 113 M |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Brainsway Ltd.
BWAY
|
94.3 M | $ 22.96 | -0.56 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 23.25 | -0.66 % | $ 250 M | ||
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M | ||
|
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | ||
|
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | ||
|
BioNano Genomics
BNGO
|
76.7 M | $ 1.59 | -0.94 % | $ 2.02 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M | ||
|
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
95.3 M | $ 6.12 | - | $ 180 M | ||
|
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B | ||
|
Castle Biosciences
CSTL
|
531 M | $ 39.59 | -0.76 % | $ 1.1 B | ||
|
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | ||
|
CareDx, Inc
CDNA
|
467 M | $ 17.02 | -1.16 % | $ 915 M | ||
|
Danaher Corporation
DHR
|
77.5 B | $ 237.64 | 1.12 % | $ 174 B | ||
|
Celcuity
CELC
|
245 M | $ 107.43 | 2.63 % | $ 4.24 B | ||
|
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | ||
|
DarioHealth Corp.
DRIO
|
96.4 M | $ 12.15 | -5.81 % | $ 345 M | ||
|
Anixa Biosciences
ANIX
|
21.6 M | $ 3.41 | -0.29 % | $ 109 K | ||
|
DexCom
DXCM
|
6.26 B | $ 66.95 | -2.16 % | $ 25.8 B | ||
|
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | ||
|
QIAGEN N.V.
QGEN
|
5.69 B | $ 48.32 | -0.27 % | $ 10.8 B | ||
|
Exact Sciences Corporation
EXAS
|
5.93 B | $ 102.13 | 0.34 % | $ 18.9 B | ||
|
Fulgent Genetics
FLGT
|
1.22 B | $ 27.84 | -0.2 % | $ 842 M | ||
|
Aspira Women's Health
AWH
|
17.4 M | - | -6.19 % | $ 10.5 M | ||
|
Guardant Health
GH
|
1.49 B | $ 110.18 | 1.32 % | $ 13.5 B | ||
|
Charles River Laboratories International
CRL
|
7.53 B | $ 220.64 | 2.38 % | $ 11.3 B | ||
|
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
6.3 B | $ 141.01 | -3.31 % | $ 22.4 B | ||
|
IQVIA Holdings
IQV
|
26.9 B | $ 243.33 | 0.06 % | $ 44.1 B | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 175.1 | -1.49 % | $ 19.4 B | ||
|
Biodesix
BDSX
|
97.2 M | $ 5.46 | -2.15 % | $ 708 M | ||
|
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 252.61 | -0.81 % | $ 21.2 B | ||
|
ICON Public Limited Company
ICLR
|
16.9 B | $ 183.13 | -2.7 % | $ 15.1 B | ||
|
IDEXX Laboratories
IDXX
|
3.29 B | $ 715.47 | 0.43 % | $ 59 B | ||
|
Lantheus Holdings
LNTH
|
1.98 B | $ 67.98 | 0.19 % | $ 4.7 B | ||
|
Agilent Technologies
A
|
10.7 B | $ 148.92 | 2.17 % | $ 45.3 B | ||
|
Biomerica
BMRA
|
5.94 M | $ 2.75 | -4.84 % | $ 6.32 M | ||
|
Bioventus
BVS
|
811 M | $ 8.02 | 0.25 % | $ 502 M | ||
|
Koninklijke Philips N.V.
PHG
|
29 B | $ 29.59 | 0.54 % | $ 20 B | ||
|
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | ||
|
Precipio
PRPO
|
18.1 M | $ 24.77 | 7.28 % | $ 32.1 M | ||
|
Mettler-Toledo International
MTD
|
3.24 B | $ 1 486.09 | 1.43 % | $ 31.5 B | ||
|
Myriad Genetics
MYGN
|
1.03 B | $ 6.53 | -0.53 % | $ 592 M | ||
|
ENDRA Life Sciences
NDRA
|
4.45 M | $ 4.6 | -0.44 % | $ 2.47 M |